New First-in-Class Phase 3 TREMFYA®▼ (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms
at Week 52
- EMEA Innovative Medicine
- New First-in-Class Phase 3 TREMFYA®▼ (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52
New First-in-Class Phase 3 TREMFYA®▼ (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52
- X (Twitter)
Copy link